Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

by | Nov 15, 2026 | Stock Market

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

Moderna reported third-quarter results that exceeded Wall Street expectations, leading the biotech company to increase its outlook for full-year performance. The company now projects 2026 revenue growth between 15% and 25%, a significant increase from its previous guidance of up to 10%. Shares rose approximately 3% in premarket trading following the announcement.

Third-quarter revenue climbed 29% to $1.31 billion compared with the year-ago period, with U.S. sales reaching $780 million and international markets contributing $533 million. The company achieved a net income of $162 million, or 38 cents per share, marking a sharp turnaround from a net loss of 51 cents per share in the same quarter the previous year. Moderna credited the outperformance to strong Covid vaccine sales in international markets bolstered by long-term government contracts, as well as contributions from newer products gaining commercial traction.

CEO Stéphane Bancel attributed the strong quarter to new product momentum and geographic diversification across Canada, the United Kingdom, and Asia. He noted that Moderna’s next-generation mRNA Covid vaccine, which received U.S. approval in May 2025, is experiencing the full-year revenue impact as contracts and vaccinations follow their typical seasonal patterns. Similarly, the company’s newly approved standalone flu vaccine, authorized in the U.S. in August, is expected to have a limited initial rollout during 2026 given timing constraints around vaccine purchasing cycles.

Bancel also highlighted that cost reduction initiatives contributed to the profitability achieved in the quarter, with both higher sales and lower operating expenses supporting the financial improvement. Recent positive late-stage trial data for Moderna’s personalized cancer vaccine candidate, developed in partnership with Merck, continued to generate interest among healthcare professionals and some investors, though the stock experienced volatility when portions of the data were leaked on social media prior to formal presentation at a medical conference.

Article Attribution | Read More at Article Source

Article summary produced by Claude AI